Trial · NCT07901413
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers | 2 years | |
| Primary | The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT) | 2 years | |
| Primary | Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD) | 2 years | |
| Primary | Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate evaluated by Investigator according to Prostate Cancer Working Group 3 (PCWG3) criteria | 2 years | |
| Primary | Participants with other tumor types: Investigator-assessed Objective response rate (ORR) according to Response Evaluation Criteria In Solid Tumors (RECIST) V1.1 criteria | 2 years | |
| Primary | The optimal dosing regimen for the subsequent study of ICP-B381 | 2 years | |
| Secondary | Maximum Concentration (Cmax) | 2 years | |
| Secondary | Time to Maximum Plasma Concentration (Tmax) | 2 years | |
| Secondary | Half-life (T1/2) | 2 years | |
| Secondary | Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t) | 2 years | |
| Secondary | Apparent Clearance Rate (CL/F) | 2 years | |
| Secondary | Terminal Apparent Volume of Distribution (Vz/F) | 2 years | |
| Secondary | Steady-state Pharmacokinetic Parameters | 2 years | |
| Secondary | ORR | 2 years | |
| Secondary | Disease Control Rate (DCR) | 2 years | |
| Secondary | Duration of Response (DOR) | 2 years | |
| Secondary | Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions) | 2 years | |
| Secondary | Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate | 2 years | |
| Secondary | Participants with prostate cancer: PSA90 response rate | 2 years | |
| Secondary | Participants with prostate cancer:12-week PSA response rate | 2 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07901413/registered